Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Acquisitions Expand Verano’s Footprint to 14 States, 15 Cultivation and Production Facilities, and 150 Dispensaries Nationwide CHICAGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp...
Dana Holding Set to Join the S&P MidCap 400 PR Newswire NEW YORK, Jan. 20, 2015 NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated...
ZERBAXA geht bestimmte gefährliche und resistente gramnegative Bakterien anErstes in den USA unter dem GAIN-Gesetz zugelassenes Antibiotikum gegen gramnegative Bakterien Cubist...
ZERBAXA s’attaque à certaines bactéries à Gram négatif graves et résistantes Premier nouvel antibiotique approuvé aux États-Unis dans le cadre de la GAIN Act pour le traitement des...
ZERBAXA addresses certain serious and resistant Gram-negative bacteriaFirst new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Cubist...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company PR Newswire BALA...
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.15 | 0.185 | 0.145 | 949107 | 0.16049456 | CS |
| 4 | -0.19 | -55.8823529412 | 0.34 | 0.355 | 0.135 | 972436 | 0.20009924 | CS |
| 12 | -0.145 | -49.1525423729 | 0.295 | 0.355 | 0.135 | 527219 | 0.23989998 | CS |
| 26 | -0.22 | -59.4594594595 | 0.37 | 0.42 | 0.135 | 527656 | 0.28021454 | CS |
| 52 | -0.33 | -68.75 | 0.48 | 0.83 | 0.135 | 998325 | 0.46496204 | CS |
| 156 | -1.53 | -91.0714285714 | 1.68 | 1.76 | 0.135 | 1106738 | 0.56779819 | CS |
| 260 | -1.53 | -91.0714285714 | 1.68 | 1.76 | 0.135 | 1106738 | 0.56779819 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
